建立免疫检查点抑制剂相关肺炎全程监测管理模式

Establish a whole-process comprehensive surveillance management mode for immune checkpoint inhibitor pneumonitis

免疫检查点抑制剂(ICIs)在多种恶性肿瘤显示了良好的抗肿瘤疗效,显著延长肿瘤患者生存期,但免疫相关不良事件不容忽视。免疫检查点抑制剂相关肺炎(CIP)是恶性肿瘤患者接受ICIs治疗后出现的肺部不良事件。在临床研究和真实世界研究的报道中,CIP的发病率约2.7%~20.0%,部分患者可能发生重症甚至是致死性的CIP,这类患者预后差。早发现、早诊断、早治疗可改善CIP患者的预后。建立ICIs免疫治疗过程中的覆盖医护和患者的CIP全程监测管理模式,有助于提高CIP的早期诊治能力,是改善患者预后的关键之举。

The application of immune checkpoint inhibitors(ICIs)has shown impressive anti-tumor efficacy across multiple malignant tumors,leading to the prolonged survival period of tumor patients.However,immune-related adverse events should not be ignored.Checkpoint inhibitor pneumonitis(CIP)is a pulmonary adverse event that can occur in malignant tumor patients after receiving ICIs treatment.The incidence of CIP has been reported to range from 2.7%to 20.0%in clinical trials and real-world research.Furthermore,some patients might suffer from serious or fatal CIP,and the prognosis of such patients will be poor.Early detection,diagnosis and treatment may improve the prognosis of these patients.The establishment of a whole-process CIP comprehensive surveillance management mode covering the health care system and patients during ICIs treatment might be helpful to improve the early diagnosis and treatment capacity of CIP,which is a key measure to improve the prognosis of these patients.